TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05432440

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The digital asthma education program
Description: The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The digital asthma education program
Description: The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.
Study: NCT05434286

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic assessment
Description: POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin
Study: NCT05846984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Skills Together Intervention
Description: Learning Skills Together is a 6-week psychoeducational intervention developed to improve caregivers' confidence when completing complex care tasks (e.g., using a gait belt). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to communicate with someone who is living with dementia, medication management, and home safety. Participants are also provided with a workbook that accompanies each lesson, and includes short readings, videos, additional resources, as well as weekly practice and reflection exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Healthy Living Intervention
Description: Participants in the Caregiver Healthy Living Intervention will participate in a 6-week educational intervention to help improve caregiver health behaviors (e.g., getting enough sleep). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to eat a healthy diet, getting enough physical activity, and taking care of mental health. Participants are also provided a workbook that includes short readings and additional resources.
Study: NCT05705453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Cord Stimulation
Description: Stimulation of the spinal cord from the epidural space.
Study: NCT06095063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Brainsway H7-Coil Deep TMS System
Description: Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Brainsway H7-Coil Deep TMS System
Description: In addition to the active H-coil, a sham coil is included in the system. The active and sham coils are connected to a control switch, which alternates between real and sham operation modes. The sham treatment will be administered daily for 4 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Cognitive training will be conducted using the BrainHQ software program.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: Cognitive training will be conducted using the BrainHQ software program.
Study: NCT06299059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
Study: NCT05461209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belantamab Mafodotin
Description: Belantamab Mafodotin will be administered as intravenous infusion.
Study: NCT06322628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSA006
Description: every 12 weeks, subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSA006
Description: every 12 weeks, subcutaneous injections
Study: NCT06320613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture therapy
Description: After disinfecting (alcohol or 0.9% Normal saline) the skin at the acupuncture point, use small tweezers to clip the handle of the needle, remove the adhesive tape and stab the acupuncture point at a perpendicular angle, and then press the thumb with moderate pressure on the snap-needle embedded needle site in order for the patient to feel localized soreness and distension as appropriate. The snap-needle was removed after 24 hours, and the pressing time point remained unchanged.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture therapy
Description: After disinfecting (alcohol or 0.9% Normal saline) the skin at the acupuncture point, use small tweezers to clip the handle of the needle, remove the adhesive tape and stab the acupuncture point at a perpendicular angle, and then press the thumb with moderate pressure on the snap-needle embedded needle site in order for the patient to feel localized soreness and distension as appropriate. The snap-needle was removed after 24 hours, and the pressing time point remained unchanged.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ginger Acupuncture Point Patch
Description: Ginger was thinly sliced and then cut into 2-3cm diameter ginger discs according to a circular mold and covered with a sterile circular dressing. The ginger compress was removed within 6 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ginger Acupuncture Point Patch
Description: Ginger was thinly sliced and then cut into 2-3cm diameter ginger discs according to a circular mold and covered with a sterile circular dressing. The ginger compress was removed within 6 hours.
Study: NCT05645835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention
Description: the digital meditation app will be installed on participants iPad or android. Lonely older adults will use the app five days a week for six weeks total. Neuroimaging will be performed before and after the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: waitlist control
Description: Participants in the waitlist group will have to wait six weeks after being screened before being able to use the meditation app after the assessment of primary and secondary endpoints
Study: NCT05281965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic acid
Description: Retinoic acid oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Retinoic acid
Description: Retinoic acid oral
Study: NCT05131620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: It is planned that VR glasses are put on 5-10 minutes before the procedure and continued throughout the procedure, and the total monitoring time will continue for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure will be applied 10 minutes before catheter extraction after CAG.
Study: NCT06322628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every 12 weeks, subcutaneous injections
Study: NCT05912582

Intervention type: RADIATION
Intervention: Intensity modulated radiation therapy (IMRT) combined with chemotherapy
Description: Intensity modulated radiation therapy (IMRT) combined with chemotherapy
Study: NCT05295888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporal Interference stimulation
Description: TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.
Study: NCT05232123

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral product formulated in MCT (medium chain triglyceride) oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
Study: NCT05578144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients Decision Aids (PDA)
Description: Patient Decision Aids (PDA) administer to case group
Study: NCT06062732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face It
Description: School-based intervention delivered over 6 weeks, including an intensive 5-day programme of activities, and pre-programme and post-programme group and 1:1 sessions. Each programme is tailored to participants' needs and uses art, storytelling, 1:1 and group experiential techniques, delivered by trained dramatherapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Services as usual
Study: NCT05639335

Intervention type: OTHER
Group type: OTHER
Intervention: No Character Control
Description: Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing no characters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Characters
Description: Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing their respective brand characters (e.g., Tony the Tiger) and a licensed character recently featured on these cereal brands (e.g., Buzz Lightyear).
Study: NCT05217654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Daily orally administration of 10mg dapagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily orally administration of 10mg dapagliflozin-placebo
Study: NCT06058260

Intervention type: OTHER
Intervention: Pediatric Quality of Life Inventory (questionnaire) and The Stanford-Binet Intelligence Scale fifth edition
Description: Quality of Life Assessment By Pediatric Quality of life Inventory. Cognitive Function Assessment By The Stanford-Binet Intelligence Scale fifth edition.

Intervention type: OTHER
Intervention: Pediatric Quality of Life Inventory (questionnaire) and The Stanford-Binet Intelligence Scale fifth edition
Description: Quality of Life Assessment By Pediatric Quality of life Inventory. Cognitive Function Assessment By The Stanford-Binet Intelligence Scale fifth edition.
Study: NCT05974774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iMAB
Description: no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA \< 0.2 ng/mL, treatment stops again.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cMAB
Description: LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)
Study: NCT04875741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural mobilization
Description: Mobilization of the structures within and around the nervous system is broadly known as Neural Mobilization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: Manual therapy technique initially developed and used by the osteopaths is known as Muscle energy techniques(MET).This technique is effective for the pain reduction, lengthening of the shortened muscle and fascia, improvement in blood circulation and promoting lymph drainage.
Study: NCT06526832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BST02
Description: BST02 is a tumor infiltrating lymphocyte product manufactured from the sample collected in the patient's tumor lesion.
Study: NCT05712733

Intervention type: OTHER
Intervention: Microbiological and histopathological investigation of bile and gallbladder wall specimens.
Description: Bile and gallbladder wall specimens will be taken from all patients included in the study. The material will be sent for microbiological and histopathological investigation.

Intervention type: OTHER
Intervention: Microbiological and histopathological investigation of bile and gallbladder wall specimens.
Description: Bile and gallbladder wall specimens will be taken from all patients included in the study. The material will be sent for microbiological and histopathological investigation.
Study: NCT05798533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-T
Description: Patients will receive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/kg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 2 weeks.~Toripalimab is recommended for patients with Melanoma.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 3 weeks.~Tislelizumab is recommended for patients with NSCLC or other tumor types.
Study: NCT06435130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention with chokeberry juices
Description: The first stage of the dietary intervention lasted 8 weeks. Study participants consumed 100 ml of chokeberry juice daily. Chokeberry juice came from ecological cultivation (Poland). Participants qualified for the study had specific biochemical parameters tested: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. Blood tests were performed in a certified external laboratory before and after 8 weeks of intervention. In addition, blood pressure and waist circumference were tested.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention with chokeberry juices and fibers
Description: The second stage of the dietary intervention lasted 4 weeks. Study participants consumed 100 ml of chokeberry juice daily and 10 g chokeberry fiber daily (from ecological cultivation, Poland). Blood tests were performed in a certified external laboratory after 4 weeks of intervention. The following blood tests were performed: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. In addition, blood pressure and waist circumference were tested.
Study: NCT05332405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: The subject will receive 3mL of ICG followed by 10 mL of sterile saline intravenously as per the Spy Elite protocol. Within minutes of the injection, the SPY machine will be turned on and focused on the nerve. The SPY machine gives a digital read out of the % fluorescence when the dye reaches the nerve. This number correlates with blood flow or vascularity.
Study: NCT04290442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block
Description: The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPANK
Description: SPANK: The block is performed in supine position, using 22 G Touhy needle, under ultrasound guidance, needle is advanced in plane to posteromedial shaft of femur taking care to avoid popliteal artery, and 0.5% ropivacaine 15 cc, dexmedetomidine 20-30mcg and dexamethasone 4 mg is injected into inner thigh above the knee provide sensory block to posterior aspect of the knee.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: ropivacaine 0.5% will be use in the block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: ropivacaine 0.5% will be use in the block
Study: NCT05009745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PGT-A Strategy
Description: PGT-A strategy involves trophectoderm biopsy, comprehensive chromosome screening (CCS) using Next Generation Screening (NGS), freezing of embryos and replacement in a frozen-thawed embryo transfer cycle.
Study: NCT05988255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static progressive stretching
Description: A stretching technique applies a mechanical progressive stretch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyclic manual stretching
Description: A stretching technique applies an intermittent manual stretch
Study: NCT05572333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP395
Description: Capsule for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule for oral use
Study: NCT06152861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Topical Cream low-dose
Description: travoprost ophthalmic topical cream low-dose once daily in the evening to both eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Topical Cream mid-dose
Description: travoprost ophthalmic topical cream mid-dose once daily in the evening to both eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Topical Cream high-dose
Description: travoprost ophthalmic topical cream high-dose once daily in the evening to both eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate ophthalmic solution, 0.5%
Description: timolol maleate ophthalmic solution, 0.5% twice daily (morning \& evening) to both eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost Ophthalmic Solution, 0.004%
Description: travoprost ophthalmic solution, 0.004% once daily in the evening to both eyes
Study: NCT05997524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was administrated as a 130 mg/m2 infusion, q3w, for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval.
Study: NCT05997251

Intervention type: OTHER
Intervention: Keeping a 1-day food consumption record by the patient
Description: Checking and receiving the 1-day food consumption record recorded by the patient by the researcher

Intervention type: OTHER
Intervention: Keeping a 1-day food consumption record by the patient
Description: Checking and receiving the 1-day food consumption record recorded by the patient by the researcher

Intervention type: OTHER
Intervention: Measurement of adiponectin level
Description: Adiponectin level will be measured for each group

Intervention type: OTHER
Intervention: Measurement of adiponectin level
Description: Adiponectin level will be measured for each group
Study: NCT06452186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: direct EMG controlled prosthetic ankle
Description: Patients are trained to use the powered prosthetic ankles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PT guided prosthetic training
Description: Amputees are trained to use prosthetic ankles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PT guided prosthetic training
Description: Amputees are trained to use prosthetic ankles